Lab worker dropping liquid onto microscope slide
Lab worker dropping liquid onto microscope slide

ASH 2022

OVERVIEW

10 - 13

Dec 2022

ASH 2022

New Orleans, LA

World’s largest network supporting clinical and scientific hematology research.

PELABRESIB PRESENTATIONS

  • Oral Presentation

    Pelabresib (CPI-0610) Combined With Ruxolitinib for JAK Inhibitor Treatment-Naïve Patients With Myelofibrosis: Durability of Response and Safety Beyond Week 24

  • Oral Presentation

    Clinical Benefit Associated With Biomarker Changes Indicative of Disease Modification in Patients With Myelofibrosis Treated With the BET Inhibitor Pelabresib as Monotherapy or in Combination With Ruxolitinib

  • Poster

    Pelabresib (CPI-0610) as Add-on to Ruxolitinib in Myelofibrosis: Durability of Response and Safety Beyond Week 24 in the Phase 2 MANIFEST Study

TAFASITAMAB PRESENTATIONS

  • Poster

    First-MIND: Final Analysis from a Phase Ib, Open-Label, Randomized Study to Assess Safety of Tafasitamab or Tafasitamab + Lenalidomide in Addition to R CHOP in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma

  • Poster

    frontMIND: A Phase III, Multicenter, Randomized, Double-Blind Study of Tafasitamab + Lenalidomide + R-CHOP versus R-CHOP Alone for Newly Diagnosed High-Intermediate and High-Risk Diffuse Large B-Cell Lymphoma

  • Poster

    L-MIND: A Safety and Efficacy Analysis of Tafasitamab in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma Receiving Treatment for at Least 2 Years

OTHER CONGRESSES

ASCO 2022

Annual meeting featuring presentations on the latest research in cancer care.

03/06 - 07/06 Chicago, IL

EHA 2022

European-based organization and congress promoting excellence in hematology.

09/06 - 12/06 Vienna, Austria

SOHO 2022

Annual meeting of global society of clinicians and scientists specializing in hematology.

28/09 - 01/10 Houston, TX

PIPELINE

Pelabresib
Tafasitamab

MorphoSys is providing the data presented at medical congresses as part of scientific exchange. The scientific information may include data/information on investigational use(s) of compounds/drugs of which the efficacy and safety have not yet been established. Information available on this website is not intended to promote or otherwise commercialize (directly or indirectly) any off-label or unapproved uses of MorphoSys’ products. Copies of congress presentations may not be reproduced without written permission from the congress and the authors.